Sanofi halts amlitelimab trials, preps Q2 2026 earnings amid AI drug discovery push

Sanofi is set to report its Q2 2026 earnings with expected EPS of $1.10 and revenue of $12.41 billion. The company halted clinical development of amlitelimab for atopic dermatitis, reflecting a strategic shift in its drug pipeline. Leadership changes and an expanded $140 million AI drug discovery partnership with Aqemia highlight Sanofi's focus on innovation and future growth. Financial metrics show solid valuation and healthy liquidity ahead of the earnings release on July 30, 2026.